Inspra列入医保了吗？

Is a selective aldosterone receptor antagonist. It is available in tablet form, Inspra (25mg, 50mg). Inspra is approved for (1) congestive heart failure after acute myocardial infarction: Inspra can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that Inspra can also be used for congestive heart failure after acute myocardial infarction; (2) Anti-hypertension: Planep can be used alone or in combination with other anti-hypertensive drugs for the treatment of hypertension.

Inspra usage and dosage

1. Congestive heart failure after acute myocardial infarction: The recommended dose is 50 mg/time, once/day. The initial dose should be 25 mg/time, once/day, and within 4 weeks, the dose should be gradually increased to 50 mg/time, once/day if the patient tolerates it.

2. Anti-hypertensive: Inspra can be used alone or in combination with other anti-hypertensive drugs. The recommended initial dose for use alone is 50mg/time, once/day. Obvious pressure-reducing effect will appear within four weeks of taking the medicine. If the pressure effect is not obvious, it can be increased to 50mg/time, 2 times/day. Higher dosages are not recommended, otherwise there is an increased risk of adverse reactions such as hyperkalemia. 

It is understood that Inspra is not currently on the market in China, so Inspra is not sold in China, and therefore Inspra has not yet entered domestic medical insurance. At present, the Indian version of Inspra is the one most used by domestic patients. The Indian version of Inspra is produced by Lupine Pharmaceuticals of India. The specification is 50mg*100 tablets and the price is equivalent to RMB 500. The price is relatively cheap, so that most patients at home and abroad can reduce their financial burden.

Storage: Store at 25°C (77°F); tolerance allowed 15°C to 30°C (59°F to 86°F).